MCo-polyR-L1

General Information


DRACP ID  DRACP00629

Peptide Name   MCo-polyR-L1

Sequence  CRRKRRRCRRDSDCPGACICRGNGYCGSGSDGGV

Sequence Length  34

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Cancer targeted peptides



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
MCF-7 Invasive breast carcinoma of no special type Carcinoma IC50>100 μM MTT assay 48h 1
PC-3 Prostate carcinoma Carcinoma IC50>100 μM MTT assay 48h 1
HT-29 Colon adenocarcinoma Carcinoma IC50>100 μM MTT assay 48h 1

Hemolytic Activity  Human red blood cells: no hemolytic activity(as show in Fig.4)

Normal (non-cancerous) Cytotoxicity  HUVEC: IC50>100 μM

Target  pigment epithelium-derived factor; somatostatin

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00629

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C139H238N60O46S6

Absent amino acids  EFHLMQTW

Common amino acids  R

Mass  426695

Pl  9.22

Basic residues  9

Acidic residues  3

Hydrophobic residues  3

Net charge  6

Boman Index  -14302

Hydrophobicity  -107.35

Aliphatic Index  22.94

Half Life 
  Mammalian: 1.2 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  1865

Absorbance 280nm  56.52

Polar residues  18

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 27734947

Title  Dual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy

Doi 10.1038/srep35347

Year  2016

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.